UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

 

x Filed by the Registrant ¨ Filed by a Party other than the Registrant

 

Check the appropriate box:

¨ Preliminary Proxy Statement

¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

¨ Definitive Proxy Statement

x Definitive Additional Materials

¨ Soliciting Material under §240.14a-12

 

OCUGEN, INC.

 

(Name of Registrant as Specified In Its Charter)

 

Payment of Filing Fee (Check the appropriate box):
x		No fee required.
¨		Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
		(1)		Title of each class of securities to which transaction applies:
		(2)		Aggregate number of securities to which transaction applies:
		(3)		Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
		(4)		Proposed maximum aggregate value of transaction:
		(5)		Total fee paid:
¨		Fee paid previously with preliminary materials.
¨		Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
		(1)		Amount Previously Paid:
		(2)		Form, Schedule or Registration Statement No.:
		(3)		Filing Party:
		(4)		Date Filed:

 

 

 

 

 

UPDATED: Ocugen Inc. Reminds Stockholders of Adjournment of
Annual Meeting to New Date and Time

 

MALVERN, PA, June 25, 2021 - Ocugen, Inc. (NASDAQ: OCGN) is reminding stockholders about the adjournment of its 2021 Annual Meeting to a new date and time.

 

The Annual Meeting was convened as initially scheduled on June 11, 2021. As there was not a sufficient number of shares represented in person or by proxy to constitute a quorum, the Annual Meeting was adjourned without conducting any business to 11:00am. Eastern Time on Friday, July 2, 2021. The reconvened Annual Meeting will be held as a virtual meeting only and the business to be conducted is as described in the Proxy Statement filed with the Securities and Exchange Commission on April 28, 2021. The record date for attendance at the Annual Meeting remains April 19, 2021.

 

Stockholders can attend the 2021 Annual Meeting of Stockholders online and submit questions during the meeting by visiting www.virtualshareholdermeeting.com/OCGN2021. They will also be able to vote their shares electronically at the Annual Meeting.

 

To access the company’s Proxy Statement, please visit the investor section of Ocugen’s website.

 

About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug — “one to many,” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com.

 

Ocugen Contact:
Ocugen, Inc.
Ken Inchausti
Head, Investor Relations and Communications
ken.inchausti@ocugen.com

 

Please submit investor-related inquiries to: IR@ocugen.com